Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Profile of veliparib and its potential in the treatment of solid tumors

1 Jul 2015

Abstract excerpt

Inhibition of poly(ADP-ribose) polymerase (PARP) is an attractive therapeutic strategy because of the importance of this pathway in restoring DNA damage. Small-molecule inhibitors of PARP appear most effective when used to treat tumors with underlying defects in DNA repair, or when combined with DNA-damaging agents. Veliparib is one of several recently developed oral inhibitors of PARP currently in clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26251615
DOI: 10.2147/ott.s69935

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Profile of veliparib and its potential in the treatment of solid tumorsPMID 26251615Read ↗

Role of PARP Inhibitors in Cancer Biology and TherapySemantic proximity Read ↗

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaSemantic proximity Read ↗

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?Semantic proximity Read ↗

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsSemantic proximity Read ↗

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group studySemantic proximity Read ↗

Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.Semantic proximity Read ↗

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.Semantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agentSemantic proximity Read ↗

Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World DataSemantic proximity Read ↗

PARP Inhibitors in Ovarian CancerSemantic proximity Read ↗

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.Semantic proximity Read ↗

A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.